Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data

Two weeks after obtaining its third cancer indication and the same day Kite CEO Christi Shaw’s departure was announced, Gilead’s antibody-drug conjugate yielded Phase II data it says will help toward full approval in urothelial cancer.

Antibody-drug conjugate
Gilead continues working toward adding to ADC Trodelvy's label • Source: Shutterstock

Gilead Sciences, Inc. unveiled new and updated positive data from a Phase II trial of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC) on 17 February, part of a dataset the company hopes will expand the antibody-drug conjugate into second-line treatment of bladder cancer.

The updated readout from Phase II TROPHY-U-01 arrived just two weeks after the Foster City, CA-headquartered company announced on 3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D